COLGATE-PALMOLIVE ($CL) posted quarterly earnings results on Friday, August 1st. The company reported earnings of $0.92 per share, missing estimates of $0.92 by $0.00. The company also reported revenue of $5,110,000,000, missing estimates of $5,179,726,315 by $-69,726,315.
You can see Quiver Quantitative's $CL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COLGATE-PALMOLIVE Insider Trading Activity
COLGATE-PALMOLIVE insiders have traded $CL stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CL stock by insiders over the last 6 months:
- SALLY MASSEY (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 10,250 shares for an estimated $936,334.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
COLGATE-PALMOLIVE Hedge Fund Activity
We have seen 727 institutional investors add shares of COLGATE-PALMOLIVE stock to their portfolio, and 920 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 5,269,140 shares (+18.3%) to their portfolio in Q1 2025, for an estimated $493,718,418
- AMUNDI removed 4,079,350 shares (-44.3%) from their portfolio in Q1 2025, for an estimated $382,235,095
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 3,101,734 shares (-41.4%) from their portfolio in Q1 2025, for an estimated $290,632,475
- BLACKROCK, INC. added 2,814,125 shares (+3.9%) to their portfolio in Q1 2025, for an estimated $263,683,512
- WELLINGTON MANAGEMENT GROUP LLP removed 2,751,011 shares (-18.6%) from their portfolio in Q1 2025, for an estimated $257,769,730
- GOLDMAN SACHS GROUP INC added 2,045,191 shares (+34.5%) to their portfolio in Q1 2025, for an estimated $191,634,396
- CITADEL ADVISORS LLC removed 1,987,597 shares (-95.1%) from their portfolio in Q1 2025, for an estimated $186,237,838
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COLGATE-PALMOLIVE Government Contracts
We have seen $24,159 of award payments to $CL over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- 8510841939!DOG FOOD: $12,446
- 8510810671!DOG FOOD: $11,713
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
COLGATE-PALMOLIVE Analyst Ratings
Wall Street analysts have issued reports on $CL in the last several months. We have seen 6 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 07/25/2025
- UBS issued a "Buy" rating on 07/17/2025
- Citigroup issued a "Buy" rating on 04/28/2025
- Wells Fargo issued a "Underweight" rating on 04/02/2025
- Piper Sandler issued a "Overweight" rating on 03/31/2025
- Raymond James issued a "Outperform" rating on 02/03/2025
- Morgan Stanley issued a "Overweight" rating on 02/03/2025
To track analyst ratings and price targets for COLGATE-PALMOLIVE, check out Quiver Quantitative's $CL forecast page.
COLGATE-PALMOLIVE Price Targets
Multiple analysts have issued price targets for $CL recently. We have seen 10 analysts offer price targets for $CL in the last 6 months, with a median target of $101.5.
Here are some recent targets:
- Andrea Teixeira from JP Morgan set a target price of $99.0 on 07/25/2025
- Peter Grom from UBS set a target price of $106.0 on 07/17/2025
- Lauren Lieberman from Barclays set a target price of $87.0 on 07/15/2025
- Filippo Falorni from Citigroup set a target price of $108.0 on 04/28/2025
- Chris Carey from Wells Fargo set a target price of $88.0 on 04/02/2025
- Korinne Wolfmeyer from Piper Sandler set a target price of $107.0 on 03/31/2025
- Mark Astrachan from Stifel set a target price of $93.0 on 02/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
